FAM
CTMX icon

Fred Alger Management’s CytomX Therapeutics CTMX Stock Holding History

Fred Alger Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-4,000
Closed -$114K – 549
2018
Q1 		$114K Buy
+4,000
New +$114K ﹤0.01% 403
2017
Q3 		– Sell
-5,000
Closed -$78K – 518
2017
Q2 		$78K Buy
+5,000
New +$75.4K ﹤0.01% 406

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Fred Alger Management's CTMX Position: Q2 2018 in Review

Fred Alger Management sold out of CytomX Therapeutics (CTMX) in Q2 2018, closing a stake of 4,000 shares — an estimated $114K sold.

Fred Alger Management first reported a position in CTMX in Q2 2017 and held it in 2 quarters. The position peaked at $114K in Q1 2018. 142 funds tracked by Wall St. Rank hold CTMX as of Q2 2018.

  • Fred Alger Management reported no remaining CytomX Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Fred Alger Management sold 4,000 CytomX Therapeutics shares in Q2 2018, an estimated $114K.
  • Fred Alger Management first reported a position in CytomX Therapeutics in Q2 2017 and held it in 2 quarters.
  • Fred Alger Management's CytomX Therapeutics position peaked at $114K in Q1 2018.
  • 142 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2018.

Based on Fred Alger Management's 13F filing for Q2 2018, filed 19 Jul 2018.